Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

被引：20

作者：

Loibl, Sibylle ^{[1
,2
]}

Huang, Chiun-Sheng ^{[3
,4
]}

Mano, Max S. ^{[5
]}

Mamounas, Eleftherios P. ^{[6
,7
]}

Geyer, Charles E. ^{[8
,9
]}

Untch, Michael ^{[10
,11
]}

Thery, Jean-Christophe ^{[12
]}

Schwaner, Ingo

Limentani, Steven ^{[13
]}

Loman, Niklas ^{[14
]}

Lubbe, Kristina ^{[15
]}

Chang, Jenny C. ^{[16
]}

Hatschek, Thomas ^{[17
]}

Tesarowski, David ^{[18
]}

Song, Chunyan ^{[18
]}

de Haas, Sanne Lysbet ^{[19
]}

Boulet, Thomas ^{[19
]}

Lambertini, Chiara ^{[19
]}

Wolmark, Norman ^{[8
,20
]}

机构：

[1] GBG, Neu Isenburg, Germany

[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] NSABP Fdn, Orlando, FL USA

[7] Orlando Hlth Canc Inst, Orlando, FL USA

[8] NSABP Fdn, Pittsburgh, PA USA

[9] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[10] AGO B, Berlin, Germany

[11] HELIOS Klinikum Berlin Buch, Berlin, Germany

[12] Ctr Henri Becquerel, Canc Ctr, Rouen, France

[13] Atrium Hlth, Charlotte, NC USA

[14] Skane Univ Hosp, Lund, Sweden

[15] Diakovere Henrietten Stift, Hannover, Germany

[16] Houston Methodist Canc Ctr, Houston, TX USA

[17] Karolinska Univ Hosp, Solna, Sweden

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Univ Pittsburgh, Pittsburgh, PA USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

NEOADJUVANT CHEMOTHERAPY; HER2; PROGNOSIS;

D O I：

10.1038/s41523-022-00477-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

引用

页数：6

共 50 条

[11] Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
Mamounas, E. P.
Untch, M.
Mano, M. S.
Huang, C-S
Geyer, C. E., Jr.
von Minckwitz, G.
Wolmark, N.
Pivot, X.
Kuemmel, S.
DiGiovanna, M. P.
Kaufman, B.
Kunz, G.
Conlin, A. K.
Alcedo, J. C.
Kuehn, T.
Wapnir, I
Fontana, A.
Hackmann, J.
Polikoff, J.
Saghatchian, M.
Brufsky, A.
Yang, Y.
Zimovjanova, M.
Boulet, T.
Liu, H.
Tesarowski, D.
Lam, L. H.
Song, C.
Smitt, M.
Loibl, S.
ANNALS OF ONCOLOGY, 2021, 32 (08) : 1005 - 1014
[12] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
Haq, Bushra
Geyer, Charles E.
WOMENS HEALTH, 2009, 5 (02) : 135 - 147
[13] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
Hudis, CA
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 12 - 13
[14] Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
Ulaner, Gary A.
Hyman, David M.
Ross, Dara S.
Corben, Adriana
Chandarlapaty, Sarat
Goldfarb, Shari
McArthur, Heather
Erinjeri, Joseph P.
Solomon, Stephen B.
Kolb, Hartmuth
Lyashchenko, Serge K.
Lewis, Jason S.
Carrasquillo, Jorge A.
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (10) : 1523 - 1528
[15] The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
Delgado, J.
Vleminckx, C.
Sarac, S.
Sosa, A.
Bergh, J.
Giuliani, R.
Enzmann, H.
Pignatti, F.
ESMO OPEN, 2021, 6 (02)
[16] ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
Hurvitz, Sara A.
Bachelot, Thomas
Bianchini, Giampaolo
Harbeck, Nadia
Loi, Sherene
Park, Yeon Hee
Prat, Aleix
Gilham, Leslie
Boulet, Thomas
Gochitashvili, Nino
Monturus, Estefania
Lambertini, Chiara
Nyawira, Beatrice
Knott, Adam
Restuccia, Eleonora
Schmid, Peter
FUTURE ONCOLOGY, 2022, 18 (32) : 3563 - 3572
[17] HER2-Positive Breast Cancer: Beyond Trastuzumab
Murphy, Conleth G.
Fornier, Monica
ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
[18] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
Guerin, Mathilde
Sabatier, Renaud
Goncalves, Anthony
BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
[19] Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Farrokh Dehdashti
Ningying Wu
Ron Bose
Michael J. Naughton
Cynthia X. Ma
Bernadette V. Marquez-Nostra
Philipp Diebolder
Cedric Mpoy
Buck E. Rogers
Suzanne E. Lapi
Richard Laforest
Barry A. Siegel
Breast Cancer Research and Treatment, 2018, 169 : 523 - 530
[20] Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
Novoa, Silvia Antolin
Escriva-de-Romani, Santiago
Ortega, Pablo Tolosa
Fernandez, Lucia Oliva
Lopez, Rafael Lopez
Gonzalez, Ana Lopez
Barrio, Pilar de la Morena
Diaz-Guardamino, Isabel Echavarria
Martinez, Jose Enrique Ales
Garate, Zita
Gonzalez-Cortijo, Lucia
CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 37

← 1 2 3 4 5 →